Overactive bladder: A clinical entity or a marketing hype?

European Urology

Volumn 47, Issue 3, 2005, Pages 273-276

  Madersbacher, Helmut ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

BEHAVIOR THERAPY; CLINICAL TRIAL; CORRELATION ANALYSIS; DETRUSOR DYSSYNERGIA; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; EDITORIAL; EMPIRICISM; FLUID INTAKE; HEALTH CARE PERSONNEL; HUMAN; MARKETING; MEDICAL LITERATURE; META ANALYSIS; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; POLYURIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; PUBLICATION; QUALITY OF LIFE; SIDE EFFECT; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; SYNDROME DELINEATION; SYSTEMATIC REVIEW; TRAINING; URINARY URGENCY; URODYNAMICS;

EID: 13844271307     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.10.015     Document Type: Editorial

References (10)

1. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
2. J.G. Blaivas Overactive bladder: symptom or syndrome? BJU Int 92 2003 521 526
3. P. Herbison, J. Hay-Smith, and G. Ellis Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review BMJ 326 2003 841 844
4. Staskin D. Personal communication. 2004.
5. M. Stöhrer, H. Madersbacher, R. Riedler, J. Wenart, and K. Dreikorn Efficacy and safety of propiverin in SCI-patients suffering from detrusor hyperreflexia - a double blind, placebo controlled clinical trial Spinal Cord 37 1999 196 200
6. H. Madersbacher, M. Stöhrer, and G. Mürtz Trospiumchlorid versus oxybutynine: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia Br J Urol 75 1995 452 456
7. I. Milsom, P. Abrams, and L. Cardozo How widespaced are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760 766
8. W. Stewart, R. Herzog, and A. Wein The NOBLE Program Research Team. Prevalence and impact of overactive bladder in the US: Results from the NOBLE program Neurourol Urodyn 20 2001 403 422
9. Y.-Ch. Tong OAB - The apocalypse. Letter to the Editor Neurourol Urodyn 22 2003 89
10. G.A. Digesu, V. Khullar, and L. Cardozo Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 22 2003 105 108